The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Antibody Drug Conjugates (ADCs)-Global Market Insights and Sales Trends 2024
Synopsis
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
The global Antibody Drug Conjugates (ADCs) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Antibody Drug Conjugates (ADCs) in various end use industries. The expanding demands from the Hospital, Clinics and Others,, are propelling Antibody Drug Conjugates (ADCs) market. Seattle Genetics Technology, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ImmunoGen Technology segment is estimated at % CAGR for the next seven-year period.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antibody Drug Conjugates (ADCs), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antibody Drug Conjugates (ADCs) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antibody Drug Conjugates (ADCs) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antibody Drug Conjugates (ADCs) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antibody Drug Conjugates (ADCs) covered in this report include Roche, Pfizer, Novartis, Genmab, Bayer, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and AbGenomics, etc.
The global Antibody Drug Conjugates (ADCs) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Global Antibody Drug Conjugates (ADCs) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antibody Drug Conjugates (ADCs) market, Segment by Type:
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Global Antibody Drug Conjugates (ADCs) market, by Application
Hospital
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antibody Drug Conjugates (ADCs) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
The global Antibody Drug Conjugates (ADCs) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Antibody Drug Conjugates (ADCs) in various end use industries. The expanding demands from the Hospital, Clinics and Others,, are propelling Antibody Drug Conjugates (ADCs) market. Seattle Genetics Technology, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ImmunoGen Technology segment is estimated at % CAGR for the next seven-year period.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antibody Drug Conjugates (ADCs), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antibody Drug Conjugates (ADCs) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antibody Drug Conjugates (ADCs) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antibody Drug Conjugates (ADCs) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antibody Drug Conjugates (ADCs) covered in this report include Roche, Pfizer, Novartis, Genmab, Bayer, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and AbGenomics, etc.
The global Antibody Drug Conjugates (ADCs) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Global Antibody Drug Conjugates (ADCs) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antibody Drug Conjugates (ADCs) market, Segment by Type:
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Global Antibody Drug Conjugates (ADCs) market, by Application
Hospital
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antibody Drug Conjugates (ADCs) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Antibody Drug Conjugates (ADCs)
1.1 Antibody Drug Conjugates (ADCs) Market Overview
1.1.1 Antibody Drug Conjugates (ADCs) Product Scope
1.1.2 Antibody Drug Conjugates (ADCs) Market Status and Outlook
1.2 Global Antibody Drug Conjugates (ADCs) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Antibody Drug Conjugates (ADCs) Market Size by Region (2018-2029)
1.4 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Region (2018-2023)
1.5 Global Antibody Drug Conjugates (ADCs) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Antibody Drug Conjugates (ADCs) Market Size (2018-2029)
1.6.1 North America Antibody Drug Conjugates (ADCs) Market Size (2018-2029)
1.6.2 Europe Antibody Drug Conjugates (ADCs) Market Size (2018-2029)
1.6.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size (2018-2029)
1.6.4 Latin America Antibody Drug Conjugates (ADCs) Market Size (2018-2029)
1.6.5 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size (2018-2029)
2 Antibody Drug Conjugates (ADCs) Market by Type
2.1 Introduction
2.1.1 Seattle Genetics Technology
2.1.2 ImmunoGen Technology
2.1.3 Immunomedics Technology
2.2 Global Antibody Drug Conjugates (ADCs) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Type (2018-2023)
2.2.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Antibody Drug Conjugates (ADCs) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Antibody Drug Conjugates (ADCs) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Antibody Drug Conjugates (ADCs) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Breakdown by Type (2018-2029)
3 Antibody Drug Conjugates (ADCs) Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinics
3.1.3 Others
3.2 Global Antibody Drug Conjugates (ADCs) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Application (2018-2023)
3.2.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Antibody Drug Conjugates (ADCs) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Antibody Drug Conjugates (ADCs) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Antibody Drug Conjugates (ADCs) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Breakdown by Application (2018-2029)
4 Antibody Drug Conjugates (ADCs) Competition Analysis by Players
4.1 Global Antibody Drug Conjugates (ADCs) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antibody Drug Conjugates (ADCs) as of 2022)
4.3 Date of Key Players Enter into Antibody Drug Conjugates (ADCs) Market
4.4 Global Top Players Antibody Drug Conjugates (ADCs) Headquarters and Area Served
4.5 Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
4.6 Competitive Status
4.6.1 Antibody Drug Conjugates (ADCs) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.1.4 Roche Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.2.4 Pfizer Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.3.4 Novartis Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.3.5 Genmab Recent Developments
5.4 Genmab
5.4.1 Genmab Profile
5.4.2 Genmab Main Business
5.4.3 Genmab Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.4.4 Genmab Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.4.5 Genmab Recent Developments
5.5 Bayer
5.5.1 Bayer Profile
5.5.2 Bayer Main Business
5.5.3 Bayer Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.5.4 Bayer Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.5.5 Bayer Recent Developments
5.6 Seattle Genetics
5.6.1 Seattle Genetics Profile
5.6.2 Seattle Genetics Main Business
5.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.6.5 Seattle Genetics Recent Developments
5.7 Takeda Pharmaceuticals
5.7.1 Takeda Pharmaceuticals Profile
5.7.2 Takeda Pharmaceuticals Main Business
5.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.7.5 Takeda Pharmaceuticals Recent Developments
5.8 AbbVie
5.8.1 AbbVie Profile
5.8.2 AbbVie Main Business
5.8.3 AbbVie Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.8.4 AbbVie Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.8.5 AbbVie Recent Developments
5.9 AbGenomics
5.9.1 AbGenomics Profile
5.9.2 AbGenomics Main Business
5.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.9.4 AbGenomics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.9.5 AbGenomics Recent Developments
5.10 ADC Therapeutics
5.10.1 ADC Therapeutics Profile
5.10.2 ADC Therapeutics Main Business
5.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.10.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.10.5 ADC Therapeutics Recent Developments
5.11 Astellas Pharma
5.11.1 Astellas Pharma Profile
5.11.2 Astellas Pharma Main Business
5.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.11.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.11.5 Astellas Pharma Recent Developments
5.12 Kairos Therapeutics
5.12.1 Kairos Therapeutics Profile
5.12.2 Kairos Therapeutics Main Business
5.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Products, Services and Solutions
5.12.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue (US$ Million) & (2018-2023)
5.12.5 Kairos Therapeutics Recent Developments
6 North America
6.1 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Antibody Drug Conjugates (ADCs) Market Dynamics
11.1 Antibody Drug Conjugates (ADCs) Industry Trends
11.2 Antibody Drug Conjugates (ADCs) Market Drivers
11.3 Antibody Drug Conjugates (ADCs) Market Challenges
11.4 Antibody Drug Conjugates (ADCs) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
